source
- Teva's experimental antibody cuts intestinal damage in celiac patients after gluten challengeTeva reported that a single injection of an experimental antibody markedly lowered intestinal damage in participants with celiac disease who continued to consume gluten daily. The study was a glut…
- Novartis’ BTK inhibitor remibrutinib cuts MS relapse rates in Phase 3, setting up FDA filingNovartis reported that its BTK inhibitor remibrutinib, already approved for chronic spontaneous urticaria, lowered annualized relapse rates in two Phase 3 studies of relapsing multiple sclerosis wh…